ArticleCancer immunology, immunotherapy : CII2025
The ATR inhibitor tuvusertib (M1774) sensitizes prostate carcinoma to natural killer cell-mediated cytotoxicity, which is further augmented by the IL-15 receptor superagonist N-803.
Cailyn A Lee et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.